Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Iambic Therapeutics has appointed Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer. Dr. Secora, formerly CFO at Recursion (NASDAQ: RXRX), brings extensive experience in technology-driven drug development, combining scientific, capital markets, and business expertise.
At Recursion, he led finance, communications, and investor relations, orchestrating collaborations with major companies like Bayer and Roche-Genentech, and raising over $1.3 billion through private and public funding rounds.
Iambic's pipeline includes IAM1363, a HER2 inhibitor in Phase 1 with data expected in 2025, along with other programs including a dual CDK2/4 inhibitor and an allosteric KIF18A inhibitor. The company's platform integrates chemical synthesis, mass spectrometry, and AI technology, demonstrating ability to advance from program initiation to Phase 1 trials in approximately 2 years.
Iambic Therapeutics ha nominato Michael Secora, Ph.D. come Chief Corporate Development Officer e Chief Financial Officer. Il Dr. Secora, ex CFO di Recursion (NASDAQ: RXRX), porta con sé una vasta esperienza nello sviluppo di farmaci guidato dalla tecnologia, combinando competenze scientifiche, nei mercati dei capitali e aziendali.
Presso Recursion, ha guidato le finanze, le comunicazioni e le relazioni con gli investitori, orchestrando collaborazioni con importanti aziende come Bayer e Roche-Genentech, e raccogliendo oltre 1,3 miliardi di dollari attraverso round di finanziamento sia privati che pubblici.
Il pipeline di Iambic include IAM1363, un inibitore HER2 in Fase 1, con dati attesi nel 2025, insieme ad altri programmi che includono un inibitore duale CDK2/4 e un inibitore allosterico KIF18A. La piattaforma dell'azienda integra sintesi chimica, spettrometria di massa e tecnologia AI, dimostrando la capacità di avanzare dall'inizio del programma fino ai trial di Fase 1 in circa 2 anni.
Iambic Therapeutics ha nombrado a Michael Secora, Ph.D. como Director de Desarrollo Corporativo y Director Financiero. El Dr. Secora, ex CFO de Recursion (NASDAQ: RXRX), aporta una amplia experiencia en el desarrollo de fármacos impulsado por la tecnología, combinando conocimientos científicos, en mercados de capitales y empresariales.
En Recursion, lideró las finanzas, comunicaciones y relaciones con inversores, orquestando colaboraciones con grandes empresas como Bayer y Roche-Genentech, y recaudando más de 1.3 mil millones de dólares a través de rondas de financiamiento privadas y públicas.
El pipeline de Iambic incluye IAM1363, un inhibidor de HER2 en Fase 1, con datos esperados para 2025, junto con otros programas que incluyen un inhibidor dual CDK2/4 y un inhibidor alostérico KIF18A. La plataforma de la empresa integra síntesis química, espectrometría de masas y tecnología de IA, demostrando la capacidad de avanzar desde la iniciación del programa hasta ensayos de Fase 1 en aproximadamente 2 años.
아이앰빅 테라퓨틱스는 마이클 세코라(Ph.D.)를 최고 기업 개발 책임자이자 최고 재무 책임자로 임명했습니다. 세코라 박사는 이전에 리커전(종목번호: RXRX)의 CFO로서 기술 중심의 약물 개발에 대한 광범위한 경험을 가지고 있으며, 과학적, 자본 시장 및 비즈니스 전문성을 결합하고 있습니다.
리커전에서 그는 재무, 커뮤니케이션 및 투자자 관계를 이끌며, 바이어(Bayer) 및 로슈-제넨텍(Roche-Genentech)과 같은 주요 기업과의 협업을 조정하고, 민간 및 공공 자금 조달을 통해 13억 달러 이상을 모금했습니다.
아이앰빅의 파이프라인에는 데이터가 2025년에 예상되는 1상 시험 중인 HER2 억제제 IAM1363이 포함되어 있으며, 이중 CDK2/4 억제제 및 비올골 상 KIF18A 억제제와 같은 다른 프로그램도 있습니다. 회사의 플랫폼은 화학 합성, 질량 분석 및 AI 기술을 통합하여 프로그램 시작에서 1상 시험까지 약 2년 만에 진행할 수 있는 능력을 보여주고 있습니다.
Iambic Therapeutics a nommé Michael Secora, Ph.D. au poste de Chief Corporate Development Officer et Chief Financial Officer. Le Dr Secora, ancien CFO de Recursion (NASDAQ: RXRX), apporte une vaste expérience dans le développement de médicaments axé sur la technologie, alliant expertise scientifique, marchés de capitaux et affaires.
Chez Recursion, il a dirigé les finances, la communication et les relations avec les investisseurs, orchestrant des collaborations avec de grandes entreprises telles que Bayer et Roche-Genentech, et levant plus de 1,3 milliard de dollars lors de rondes de financement privées et publiques.
Le pipeline d'Iambic comprend IAM1363, un inhibiteur HER2 en Phase 1 avec des données attendues en 2025, ainsi que d'autres programmes incluant un inhibiteur dual CDK2/4 et un inhibiteur allostérique KIF18A. La plateforme de l'entreprise intègre synthèse chimique, spectrométrie de masse et technologie IA, démontrant la capacité de progresser depuis l'initiation du programme jusqu'aux essais de Phase 1 en environ 2 ans.
Iambic Therapeutics hat Michael Secora, Ph.D. zum Chief Corporate Development Officer und Chief Financial Officer ernannt. Dr. Secora, zuvor CFO bei Recursion (NASDAQ: RXRX), bringt umfangreiche Erfahrung in der technologiegetriebenen Arzneimittelentwicklung mit, indem er wissenschaftliche, kapitalmarktorientierte und geschäftliche Expertise kombiniert.
Bei Recursion führte er die Finanzen, die Kommunikation und die Investor Relations, orchestrierte Kooperationen mit großen Unternehmen wie Bayer und Roche-Genentech und sammelte über 1,3 Milliarden Dollar durch private und öffentliche Finanzierungsrunden.
Das Pipeline von Iambic umfasst IAM1363, einen HER2-Hemmer in Phase 1, dessen Daten für 2025 erwartet werden, sowie weitere Programme wie einen dualen CDK2/4-Hemmer und einen allosterischen KIF18A-Hemmer. Die Plattform des Unternehmens integriert chemische Synthese, Massenspektrometrie und KI-Technologie und zeigt die Fähigkeit, vom Programmstart bis zu Phase-1-Studien in etwa 2 Jahren voranzukommen.
- Secured experienced executive with proven track record in raising capital ($1.3B at Recursion)
- Strong pipeline development with Phase 1 trial data expected in 2025
- Demonstrated efficiency in drug development (2-year timeline from program start to Phase 1)
- Established track record in securing major industry partnerships
- None.
Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion
Michael Secora, PhD, Chief Corporate Development Officer and Chief Financial Officer, Iambic Therapeutics (Photo: Business Wire)
“Michael is a unique and effective leader with experience as a scientist, investor, and operator. He has demonstrated strategic and tactical success leading both scientific and technical teams as well as business-related and capital raising efforts,” said Tom Miller, Ph.D., Co-Founder and CEO of Iambic. “More importantly, Michael is passionate about the increased inclusion of technology within the life sciences to transform drug discovery and development. We are excited to welcome Michael to Iambic and look forward to driving our scientific and business objectives forward together."
For over a decade, Dr. Secora has been a leader in defining the value proposition for technology-driven drug development, drawing on his scientific, capital markets and business expertise. At Recursion (NASDAQ: RXRX), he led finance, communications, and investor relations activities as well as corporate strategy for translating value both internally and externally across Recursion's internal pipeline, external partnerships, and data. Dr. Secora led efforts related to Recursion's entering collaborations with Bayer, Roche-Genentech, NVIDIA, Google, Tempus, and others; combining with Exscientia (EXAI), Cyclica, Valence, and Vium; and raising over
"There are many things that I am excited about at Iambic. First, committed leadership - I admire how Tom and Fred left their professorships at Caltech and Bristol to found and lead Iambic. Second, experimental platform - I am impressed with the integration and automation of chemical synthesis, mass spectrometry, target and pathway deconvolution, and data flow optimization. Third, AI-technology - I believe that Iambic's expertise in active learning and multimodal transformer models has created industry-leading computational tools. Lastly, clinical pipeline advancement - Iambic has demonstrated an ability to go from beginning a program to a Phase 1 clinical trial in approximately 2 years, which is extraordinarily fast," said Dr. Secora.
Iambic’s pipeline includes IAM1363, a potential best-in-class, highly selective and brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1 study with data anticipated in 2025, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs.
Dr. Secora went on to say, “I have been impressed with Iambic's development over the last few years as well as the strength of Iambic's board, scientific advisors, and partners. As a scientist and investor, I believe in the increasing inclusion of technology into many aspects of our way of life. As a leader, I choose to serve organizations that have the potential for substantial and long-term positive impact. I see Iambic having such an impact in the life science and technology industries now and into the future."
Prior to Recursion, Dr. Secora had a successful 10-year investing career at Laurion Capital as Managing Director and Head of Capital Markets and Venture, where he focused on emerging technologies and the life sciences and was an early advocate and investor in the TechBio space. Dr. Secora is an alumnus of
About Iambic’s AI-Driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.
About Iambic Therapeutics
Founded in 2019 and headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106188573/en/
Jason Glashow
Glashow Strategic Communications for Iambic
Jason.Glashow@iambic.ai
Source: Iambic Therapeutics
FAQ
What is Michael Secora's track record in fundraising at Recursion (RXRX)?
When will Iambic Therapeutics' IAM1363 Phase 1 trial data be available?
How long does Iambic Therapeutics typically take to advance from program initiation to Phase 1 trials?
What are the key drug candidates in Iambic Therapeutics' pipeline?
